Regenxbio announced that the FDA has placed a clinical hold on its investigational gene therapy, RGX-121, for Hunter Syndrome due to asymptomatic spine MRI findings in five participants. This regulatory roadblock means the company does not expect to resubmit the Biologics License Application (BLA) in the near term, significantly delaying the potential market entry of this key pipeline asset.
Regenxbio's investigational gene therapy, RGX-121, for Hunter Syndrome has been placed on clinical hold by the FDA. This decision stems from the discovery of asymptomatic spine MRI findings in five participants, which, while deemed nonserious by investigators, has prompted the FDA's action. This is a significant setback for Regenxbio, as it delays the potential BLA resubmission and thus the commercialization timeline for RGX-121, a crucial product in their pipeline. The short-term implication is a sharp negative reaction in RGNX stock, as evidenced by the premarket trading. Long-term, the company will need to address the FDA's concerns, which could involve further studies or monitoring, adding to development costs and time, and potentially impacting the drug's ultimate approval and market opportunity.